BIAL-Portela & Cia SA

The €11 million Series A financing brings together Biovance Capital, the European Innovation Council (EIC) Fund and Arcano Partners’ Impacto Andalucía Innovación y Desarrollo SICC, S.A.U. Vaxdyn, a Spanish biotech company, is developing vaccines against antibiotic-resistant bacteria, one of the most urgent and fastest-growing global health threats The financing will fund the first-in-human Phase 1 clinical trial of Vaxdyn’s lead vaccine candidate, K-VAX Impacto Andalucía Innovación y Desarrollo SICC, S.A.U. is one of the funds selected by the European Investment Bank to deploy the RDI and Digital Andalucia financial instrument, financed by the ERDF programme and the Regional Government of Andalusia SEVILLE, SPAIN – 7 Sep 2026 – Biovance Capital, the European Innovation Council (EIC) Fund and Arcano Partners’ Impacto Andalucía Innovación y Desarrollo SICC, S.A.U. have invested €11 million in Spanish biotech company Vaxdyn S.L. (“Vaxdyn”) through its Series A financing round. Biovance Capital led the round with a €4 million investment, while the fund managed by Arcano Partners invested €3.6 million. Impacto Andalucía Innovación y Desarrollo SICC, S.A.U. (https://arcanofdiandalucia.com/) is one of the funds selected by the European Investment Bank to deploy the RDI and Digital Andalucia financial instrument, financed by the ERDF programme and the Regional Government of Andalusia through the Regional Ministry of Economy, Finance and European Funds. Arcano has developed a dedicated public funds platform specialized in the management of public funds, supported by an experienced team with a strong track record in mobilizing European and regional resources through market-based financial instruments. Through Impacto Andalucía Innovación y Desarrollo, Arcano manages €55 million earmarked for projects and/or companies linked to Andalusia, driving investment and the implementation of projects in the fields of R&D, innovation and digitalisation in this region, channelling long-term resources into equity transactions (capital increases), quasi-equity (convertible notes, participatory loans, etc.) or debt of up to 15 million euros, depending on requirements. “We are launching this fund to reach where traditional financing cannot. The Andalusian Government’s goal is clear: no promising project with Andalusian DNA should ever fail to see the light of day due to a lack of resources,” said Carolina España, Third Vice-President of the Regional Government of Andalusia and Regional Minister for Economy, Finance and European Funds. Vaxdyn is headquartered in Seville and is developing vaccines against dangerous antimicrobial-resistant (AMR) bacteria, including Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa. These pathogens are among the most critical threats identified by the World Health Organisation, and Vaxdyn has developed several vaccine candidates against them using its proprietary platform. AMR bacteria are already associated with an estimated 541,000 deaths annually across the WHO European Region, and 204,000 more each year in the US, with 4.95 million deaths worldwide linked to drug-resistant infections annually. Without intervention, mortality due to AMR could reach 10 million deaths per year by 2050, surpassing cancer as the world’s biggest killer. The proceeds from this Series A financing will enable Vaxdyn to conduct a Phase 1 clinical trial for K-VAX, its most advanced vaccine candidate against Klebsiella pneumoniae and Acinetobacter baumannii. This financing round will also be complemented by additional non-dilutive support from the EIC Accelerator and CARB-X, a global public-private partnership dedicated to supporting early-stage antibacterial development. “We are delighted to support Vaxdyn as it advances K-VAX, a potentially life-saving vaccine, towards the clinic. This marks our third investment from Fund I and our second in Southern Europe, reflecting our commitment to this region given the exceptional potential of its biotech ecosystem”, said Ricardo Perdigão Henriques, PhD, Managing Partner of Biovance Capital. “Our investment in Vaxdyn builds on a longstanding relationship with the company that started in 2021, when we first invested through our predecessor fund.” “Antimicrobial resistance is one of the most pressing global health challenges of our time, and we look forward to supporting Vaxdyn’s clinical development of its differentiated and patented vaccine candidate, K-VAX, which has the potential to protect against drug-resistant and life-threatening bacterial pathogens, including those associated with severe antibiotic-resistant pneumonia, urinary tract infections, bloodstream infections, among other major infectious diseases”, said André Albergaria, PhD, Principal at Biovance Capital. Cristina Reina, Managing Director, Real Estate & Public Funds at Arcano Partners, said: “Our participation in this transaction underscores Arcano Partners’ commitment to innovative companies with the potential to deliver tangible impact in areas that are critical to society. Vaxdyn is a clear example of the strength of Andalusia’s and Spain’s biotech ecosystem, and of how collaboration between private capital and public instruments can accelerate the development of high value-added solutions.” “This funding round marks a critical step in Vaxdyn’s evolution into a clinical-stage company, allowing us to clinically validate a promising vaccine platform designed to combat antimicrobial resistance”, said Juanjo Infante, PhD, Chief Executive Officer of Vaxdyn. “We are pleased to welcome Biovance Capital as lead investor and to continue working with a strong syndicate that shares our ambition to develop vaccines against life-threatening antibiotic-resistant infections.” About Biovance Capital Biovance Capital is Portugal’s leading life sciences investor. The company manages Biovance Capital Fund I, a € 60 million venture capital fund backed by the European Investment Fund and the European Commission through the Portugal Tech and InvestEU programmes, the largest Portuguese pharmaceutical company BIAL, the national promotional bank Banco Português de Fomento, and private investors such as Caixa Capital, Ageas Pensões, and Fundo de Pensões EDP, in addition to other private investors from the USA and Europe. The fund invests in early-stage drug development companies across Europe, with a special focus on Southern Europe. About Arcano Arcano Partners founded in 2003, is an independent global firm with more than 20 years of experience in financial advisory and international asset management. Arcano currently operates across four business areas: Asset Management, with more than €14.5 billion managed and advised since the launch of its activity in 2006, across six asset classes: Private Equity, Credit Strategies, Real Estate, Sustainable Infrastructure, Venture Capital and Aviation Finance. Arcano has a strong focus on sustainability and responsible investment and is recognised as a leading asset manager in ESG. Investment Banking, providing advisory services on M&A, refinancing, restructuring and capital markets transactions for companies across a wide range of sectors. Arcano combines sector-specialised teams with a transversal technology/digital approach. Research and Strategic Advisory, delivering differentiated economic, real estate and market analysis, as well as geopolitical and technology trend insights at both local and global levels. This analysis supports better decision-making, particularly in highly uncertain environments where the cost of mistakes can be significant and can be mitigated through high-quality analysis. Asset Financing, enabling investors to participate in the structuring of financing solutions for tangible and intangible assets in Spain. Arcano has a team of more than 260 professionals of over 20 nationalities, with seven offices across Europe and the United States, and has become one of Europe’s leading independent firms in private markets . About the EIB Group The European Investment Bank Group (EIB Group) is the financial arm of the European Union, owned by its 27 Member States, and is one of the world’s largest multilateral development banks. In 2025, the EIB Group signed €100 billion in new financing and advisory services for more than 870 high-impact projects across its eight core priorities, which contribute to the EU’s strategic objectives: climate action and the environment, digitalisation and technological innovation, security and defence, territorial cohesion, agriculture and the bioeconomy, social infrastructure, global partnerships, and the Savings and Investments Union. Beyond long-term lending for major infrastructure, the EIB Group attracts private investment for innovative high-risk companies and projects, and plays an increasingly important role in European venture debt, venture capital, guarantee and securitisation markets. With the support of the 27 EU governments, the EIF has joined forces with institutional investors in a pan-European alliance to mobilise up to €80 billion for investment in innovative companies scaling up to become global leaders. This agreement will broaden the reach and scale of the highly successful European Tech Champions Initiative, which, since its launch three years ago, has helped create 15 European mega-funds and supported the growth of 45 companies, including 12 “unicorns”. In Spain, the EIB Group carried out financing and investment operations totalling approximately €11 billion in 2025, complemented by an additional €2.9 billion through the Regional Resilience Fund under NextGenerationEU loans. Photographs of EIB Group representatives and headquarters, as well as logo files and B-roll video footage for media use, are available here . About Vaxdyn Vaxdyn is a Spanish biotech company dedicated to developing preventive vaccines against antibiotic-resistant bacteria. Headquartered in Seville, the company is advancing a proprietary platform designed to generate vaccines for prevention of diseases caused by some of the highest-priority pathogens affecting global health. Its lead candidate, K-VAX, designed to prevent diseases caused by Klebsiella pneumoniae and Acinetobacter baumannii, is ready to be evaluated in a Phase 1 clinical trial. CEO Vaxdyn Contact Juan José Infante juanjo.infante@vaxdyn.com Media Vaxdyn Contact Leyla M. Sánchez Palancar leyla.sanchez@vaxdyn.com Share this Post this

上海，一名49岁的晚期胃癌患者，为搏一线生机，报名参加新药临床试验。可输完试验药物的当晚，他就突发脑出血，做完开颅手术后，在ICU抢救了一个多月，最后还是没能救回来。家属说，当初并没有被告知会有脑出血这类致命风险。出事之前，这家药企还签过科研伦理承诺书，承诺会把试药患者的安全放在第一位。后来有记者联系药企了解情况，没想到遭到高管怒怼。 这名患者姓占，此前一直因胃窦癌反复化疗，肿瘤已经侵犯到横结肠和系膜根部，手术根治的路子早就被堵死了，之前用过的几种化疗方案效果也都不理想。 占某后来在海军军医大学第一附属医院，也就是上海长海医院就诊，经过评估后，医生认为他符合条件，可以参加一款名叫IMC002的CAR-T细胞疗法临床试验，这款药针对的是CLDN18.2靶点，主要用于晚期胃癌和胃食道结合部腺癌患者。 研发这款药的公司叫易慕峰生物，成立于2020年，创始人孙敏敏是复旦大学毕业的博士，公司核心团队此前推动过国内首个CAR-T药物的上市申请，在业内算是有底子的团队。 就在占某出事前不久，易慕峰刚在公开场合签下科研伦理自律承诺书，白纸黑字写着要把试药患者的安全放在首位。 占某的家属程女士后来回忆，占某之前做化疗从没出过问题，能吃能睡能走能聊，化疗结束两天后一切正常，偏偏是输注了IMC002之后短短几个小时，就发生了危及生命的颅内大出血。 程女士认为，用药前后的时间线摆在那里，试验药物就算不是唯一原因，也极有可能是直接诱因，而且当初签的风险告知书里，根本没有明确写清楚会有脑出血这种致命风险，这等于剥夺了占某和家人本该有的知情权和选择权。 2016年1月，法国生物制药公司Bial研发的一款实验性止痛药，委托雷恩市的Biotrial机构做一期人体试验，几名健康志愿者连续服药数日后，其中一人出现严重神经系统症状，抢救无效于1月17日脑死亡，另外5人也出现不同程度脑损伤。 调查后发现，Biotrial在志愿者出现早期异常反应时没有及时暂停给药，这才酿成大祸。这起事故后来一直被业内当作反面教材，提醒药企在受试者出现异常时该不该立刻叫停，往往决定了事态最终会滑向哪里。 事后有媒体记者致电易慕峰的董事想了解情况，对方却在电话里发了火，直接怼记者滚开、烦死了。这家企业前脚刚高调签下伦理承诺书，后脚试药出了人命，面对追问的态度却如此嚣张，落差实在太大。 眼下易慕峰只表态会配合相关部门调查，对高管怒怼记者一事，始终没有道歉解释。占某的悲剧到底是不是试验药物导致，还得等官方调查结论出来才能说清楚。

Dr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis Appointment further strengthens Entera’s clinical execution team and late-stage development capabilities ahead of planned EB613 Phase 3 initiation TEL AVIV, Israel, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of Riccardo Paolo Camisasca, M.D., as Chief Medical Officer. Dr. Camisasca is a physician, clinical pharmacologist and global pharmaceutical executive with more than 30 years of experience spanning clinical development, medical affairs, regulatory strategy and R&D leadership. Most recently, he served as Global Head of Research & Development at Sumitomo Pharma Switzerland. “I am thrilled to welcome Riccardo to the Entera team. Riccardo’s appointment represents a further strengthening of our clinical leadership as we transition into late-stage clinical execution and advance our broader oral peptide pipeline,” said Miranda Toledano, Chief Executive Officer of Entera. “Riccardo brings the rare combination of successfully developing drugs across disparate global R&D organizations. He is thoughtful, rigorous and most importantly, immediately synergizes with our existing clinical operations and development team.” “Entera has reached an important inflection point, with a scarce oral peptide platform, and a potentially transformational asset in EB613 as the first oral anabolic treatment for osteoporosis,” said Dr. Camisasca. “I have spent my career advancing medicines through increasingly complex stages of clinical development, and I believe Entera has built a strong foundation for its next phase of growth. I look forward to working with Miranda and the team to execute the EB613 Phase 3 program with the discipline required for registrational development and to help translate the potential of Entera’s broader pipeline into meaningful therapies for patients.” Dr. Camisasca is a physician with more than 30 years of experience spanning clinical development, medical affairs, regulatory strategy and R&D leadership. Most recently, he served as Global Head of Research & Development at Sumitomo Pharma Switzerland, where he led the integration of the R&D organizations across Urovant, Enzyvant, Altavant, and Myovant. In that role he was responsible for clinical development, global trial execution and strategic alliance management across all four portfolios. Previously, he led the clinical development and medical affairs divisions at Bial, where he managed a team of approximately 90 people. He has also held a series of positions of increasing responsibility at Syneos Health, Takeda and Novartis. Over his career, Dr. Camisasca has worked across the development continuum, from clinical pharmacology and early development through Phase 3 studies and commercialization, with therapeutic experience spanning cardiovascular and metabolic diseases, obesity, rare diseases, neuroscience, urology and women’s health. Earlier in his career, Dr. Camisasca spent approximately 10 years as a physician and researcher at San Raffaele Hospital in Milan, including work in endocrinology and metabolic disease. He earned his Medical Degree with honors and specialized in Clinical Pharmacology at the University of Milan. About EB613 Substantial evidence supports the efficacy of anabolic therapies over anti-resorptive agents for lowering fracture risk in osteoporosis patients at high risk. However, all available anabolic therapies are administered by subcutaneous (SC) injection and used in a minority of eligible patients. Entera’s EB613 program (oral PTH(1-34), teriparatide) is being developed as the first oral, once-daily anabolic tablet treatment for osteoporosis. Entera completed a Phase 2, 6-month, 161-patient, placebo-controlled study that met all biomarker and BMD endpoints without significant safety concerns in women with postmenopausal osteoporosis or low BMD (JBMR 2024). EB613 produced rapid dose-proportional increases in biochemical markers of bone formation, reductions in markers of bone resorption, and increases in lumbar spine, total hip, and femoral neck BMD. The effects of EB613 on trabecular and cortical bone using 3D-DXA showed increases with EB613 compared to placebo on a variety of indices, including integral volumetric BMD and trabecular volumetric BMD, cortical thickness, and cortical surface BMD. Mechanistically, the findings suggest that bone strengthening and fracture resistance may occur rapidly with EB613. Furthermore, the data are consistent with that of published subcutaneous teriparatide at the 6-month time point. About Entera Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages a disruptive and proprietary technology platform (N-Tab®) and its pipeline of first-in-class oral peptide programs. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet for osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n = 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is also developing the first oral Long Acting PTH(1-34) tablet as a replacement therapy for patients with hypoparathyroidism (EB612), the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide tablet for the treatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health, Inc. For more information on Entera, visit or follow us on LinkedIn , Twitter , and Facebook . Cautionary Statement Regarding Forward Looking Statements Various statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy, clinical development activities, collaboration arrangements and expected financial and operational results are forward-looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera’s forward-looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s ability to establish and maintain development and commercialization collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statement Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10-K filed with the SEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law. Company Contact: IR@enterabio.com